The commercial production of S Betamethasone Discodium phos. using the modified process through own indigenous R&D efforts was tmenced by M/s Glaxo India Ltd. on 1.1.1890.

i rices of, Parachlorometxyleno], D>xy-dine and other drugs

273. SHRI JAGIR SINGH DARD; SHRI RAJNI RANJAN SAHU:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to re. fer to the answer to Unstarred Ques. 1369 given in the Rajya Sabha on 4th August^ 1994 and state:

(a) what action has the Ministry taken on the recommendation of the BICP in respect of Doxycycline, Nal- Acid, Paratihlorometxyleno^ Framycetin Sulphate and other drugs where prices have not been notified;

(b) when was the recommendation of the BICP in respect of each of the above drugs received and at what it stands at present;

(c) when did validity of exemption of Glipizic[1]. and Povidine Iodine expire and what steps have been taken to fix their prices; and

(d) what was the price of Cemiti. dine and Verapamilon which the formulation prices were based in September, 1987, when were the formulation prices revised thereafter and on what price of the bulk drugs are they based at present ?

THE MINISTER OF STATE IN THE, MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUAR-DO FALEIRO): (a) and (b) The prices of all hese four bulk drugg have since been notified.

(c) The validity periods of exem. ption from price control in respect of bulk drugs Glipizide and Povidine Iodine have not expired.

(d) Under DPCO 1987, the prices of Cemitiding formulations and Verapamil formulations were fixed in Juno; 1988 and November; 1989 res. put-lively which were based on the weighted average landed cost uf imported bulk drugs.The prices of Cemi-tidine formulations have not been re. vised. The prices of Verapamil formulations were revised downward in 1994 based on the weighted *i* coat of Rs. 8354.24 kg. of imported bulk-drug.

Cost of Fumycin Cap

274. SHRI JAGIR SINGH DARD: SHRI RAJNI RANJAN SAHU:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that Fumycin Capsules are being sold at almost far times than the other brands of similar formulations of other companies;

(b) if so, what is the price J' each strength and pack of Fumycin capsule and I.V. Injection and what is the price of each of other companies;

(c) what is the MAPE taken by the producer of Fumycin and what is the bulk drug involved;

(d) who is the producer of Fumycin brand of formulation and what is the composition of each and what price of bulk drug is taken;

(e) whether it is a fact that these formulations are out of price control if so; whether the Ministry has exa. mined tho break up as required under DPCO; and

(f) if so; what is Govt's reacti< and what steps are being taken • stop over profiteering?